O	0	6	Simian	Simian	JJ	B-NP
O	7	12	virus	virus	NN	I-NP
O	13	15	40	40	CD	I-NP
O	16	21	large	large	JJ	I-NP
O	22	23	T	T	NN	I-NP
O	24	31	antigen	antigen	NN	I-NP
O	32	35	and	and	CC	O
O	36	39	two	two	CD	B-NP
O	40	51	independent	independent	JJ	I-NP
O	52	53	T	T	NN	I-NP
O	53	54	-	-	HYPH	I-NP
O	54	61	antigen	antigen	NN	I-NP
O	62	70	segments	segment	NNS	I-NP
O	71	80	sensitize	sensitize	VBP	B-VP
B-Cell	81	86	cells	cell	NNS	B-NP
O	87	89	to	to	TO	B-PP
O	90	99	apoptosis	apoptosis	NN	B-NP
O	100	109	following	follow	VBG	B-PP
O	110	119	genotoxic	genotoxic	JJ	B-NP
O	120	126	damage	damage	NN	I-NP
O	126	127	.	.	.	O

O	129	132	The	The	DT	B-NP
O	133	139	simian	simian	JJ	I-NP
O	140	145	virus	virus	NN	I-NP
O	146	148	40	40	CD	I-NP
O	149	150	(	(	(	O
O	150	154	SV40	SV40	NN	B-NP
O	154	155	)	)	)	O
O	156	161	large	large	JJ	B-NP
O	162	167	tumor	tumor	NN	I-NP
O	168	169	(	(	(	O
O	169	170	T	T	NN	B-NP
O	170	171	)	)	)	O
O	172	179	antigen	antigen	NN	B-NP
O	180	182	is	be	VBZ	B-VP
O	183	193	sufficient	sufficient	JJ	B-ADJP
O	194	196	to	to	TO	B-VP
O	197	206	transform	transform	VB	I-VP
B-Cell	207	212	cells	cell	NNS	B-NP
O	213	215	in	in	IN	B-PP
O	216	224	cultures	culture	NNS	B-NP
O	225	228	and	and	CC	O
O	229	235	induce	induce	VB	B-VP
B-Cancer	236	242	tumors	tumor	NNS	B-NP
O	243	245	in	in	IN	B-PP
O	246	258	experimental	experimental	JJ	B-NP
O	259	266	animals	animal	NNS	I-NP
O	266	267	.	.	.	O

O	268	282	Transformation	Transformation	NN	B-NP
O	283	285	of	of	IN	B-PP
O	286	293	primary	primary	JJ	B-NP
B-Cell	294	299	cells	cell	NNS	I-NP
O	300	302	in	in	IN	B-PP
O	303	311	cultures	culture	NNS	B-NP
O	312	320	requires	require	VBZ	B-VP
O	321	325	both	both	CC	O
O	326	336	overcoming	overcoming	JJ	B-NP
O	337	343	growth	growth	NN	I-NP
O	344	350	arrest	arrest	NN	I-NP
O	351	353	by	by	IN	B-PP
O	354	365	stimulating	stimulate	VBG	B-VP
O	366	369	the	the	DT	B-NP
B-Cell	370	374	cell	cell	NN	I-NP
O	375	380	cycle	cycle	NN	I-NP
O	381	384	and	and	CC	O
O	385	393	blocking	block	VBG	B-VP
B-Cell	394	398	cell	cell	NN	B-NP
O	399	404	death	death	NN	I-NP
O	405	415	activities	activity	NNS	I-NP
O	416	426	presumably	presumably	RB	B-VP
O	427	436	activated	activate	VBN	I-VP
O	437	439	by	by	IN	B-PP
O	440	448	oncogene	oncogene	NN	B-NP
O	448	449	-	-	HYPH	O
O	449	457	mediated	mediate	VBN	B-NP
O	458	476	hyperproliferation	hyperproliferation	NN	I-NP
O	477	484	signals	signal	NNS	I-NP
O	484	485	.	.	.	O

O	486	489	The	The	DT	B-NP
O	490	495	study	study	NN	I-NP
O	496	505	presented	present	VBN	B-VP
O	506	510	here	here	RB	B-ADVP
O	511	519	examined	examine	VBD	B-VP
O	520	523	the	the	DT	B-NP
O	524	531	ability	ability	NN	I-NP
O	532	534	of	of	IN	B-PP
O	535	543	specific	specific	JJ	B-NP
O	544	551	regions	region	NNS	I-NP
O	552	555	and	and	CC	I-NP
O	556	566	activities	activity	NNS	I-NP
O	567	569	of	of	IN	B-PP
O	570	571	T	T	NN	B-NP
O	572	579	antigen	antigen	NN	I-NP
O	580	582	to	to	TO	B-VP
O	583	591	modulate	modulate	VB	I-VP
O	592	601	apoptosis	apoptosis	NN	B-NP
O	602	604	in	in	IN	B-PP
B-Cell	605	610	cells	cell	NNS	B-NP
O	611	618	treated	treat	VBN	B-VP
O	619	623	with	with	IN	B-PP
O	624	627	the	the	DT	B-NP
O	628	637	genotoxic	genotoxic	JJ	I-NP
O	638	643	agent	agent	NN	I-NP
O	644	645	5	5	CD	I-NP
O	645	646	-	-	HYPH	I-NP
O	646	658	fluorouracil	fluorouracil	NN	I-NP
O	659	660	(	(	(	O
O	660	661	5	5	CD	B-NP
O	661	662	-	-	HYPH	I-NP
O	662	664	FU	FU	NN	I-NP
O	664	665	)	)	)	O
O	665	666	.	.	.	O

O	667	670	The	The	DT	B-NP
O	671	678	results	result	NNS	I-NP
O	679	685	showed	show	VBD	B-VP
O	686	690	that	that	IN	B-SBAR
O	691	694	the	the	DT	B-NP
O	695	705	expression	expression	NN	I-NP
O	706	708	of	of	IN	B-PP
O	709	713	full	full	JJ	B-NP
O	713	714	-	-	HYPH	I-NP
O	714	720	length	length	NN	I-NP
O	721	722	T	T	NN	I-NP
O	723	730	antigen	antigen	NN	I-NP
O	731	739	rendered	render	VBD	B-VP
O	740	743	rat	rat	NN	B-NP
B-Cell	744	750	embryo	embryo	NN	I-NP
I-Cell	751	762	fibroblasts	fibroblast	NNS	I-NP
O	763	764	(	(	(	O
B-Cell	764	767	REF	REF	NN	B-NP
O	767	768	)	)	)	O
O	769	778	sensitive	sensitive	JJ	B-ADJP
O	779	781	to	to	TO	B-PP
O	782	783	5	5	CD	B-NP
O	783	784	-	-	HYPH	I-NP
O	784	786	FU	FU	NN	I-NP
O	786	787	-	-	HYPH	B-NP
O	787	794	induced	induce	VBN	I-NP
O	795	804	apoptosis	apoptosis	NN	I-NP
O	804	805	.	.	.	O

O	806	810	Thus	Thus	RB	B-ADVP
O	810	811	,	,	,	O
O	812	819	neither	neither	CC	O
O	820	823	the	the	DT	B-NP
O	824	827	p53	p53	NN	I-NP
O	827	828	-	-	HYPH	O
O	828	835	binding	bind	VBG	B-VP
O	836	842	region	region	NN	B-NP
O	843	846	nor	nor	CC	O
O	847	850	the	the	DT	B-NP
O	851	854	Bcl	Bcl	NN	I-NP
O	854	855	-	-	HYPH	B-NP
O	855	856	2	2	CD	I-NP
O	857	865	homology	homology	NN	I-NP
O	866	872	region	region	NN	I-NP
O	873	875	of	of	IN	B-PP
O	876	877	T	T	NN	B-NP
O	878	885	antigen	antigen	NN	I-NP
O	886	889	was	be	VBD	B-VP
O	890	900	sufficient	sufficient	JJ	B-ADJP
O	901	903	to	to	TO	B-VP
O	904	911	prevent	prevent	VB	I-VP
B-Cell	912	916	cell	cell	NN	B-NP
O	917	922	death	death	NN	I-NP
O	923	930	induced	induce	VBN	B-VP
O	931	933	by	by	IN	B-PP
O	934	937	the	the	DT	B-NP
O	938	941	DNA	DNA	NN	I-NP
O	941	942	-	-	HYPH	O
O	942	950	damaging	damage	VBG	B-VP
O	951	956	agent	agent	NN	B-NP
O	956	957	.	.	.	O

O	958	959	T	T	NN	B-NP
O	959	960	-	-	HYPH	I-NP
O	960	967	antigen	antigen	NN	I-NP
O	967	968	-	-	HYPH	O
O	968	976	mediated	mediate	VBN	B-NP
O	977	990	sensitization	sensitization	NN	I-NP
O	991	999	occurred	occur	VBD	B-VP
O	1000	1013	independently	independently	RB	B-ADVP
O	1014	1016	of	of	IN	B-PP
O	1017	1031	retinoblastoma	retinoblastoma	NN	B-NP
O	1032	1039	protein	protein	NN	I-NP
O	1040	1042	or	or	CC	O
O	1043	1046	p53	p53	NN	B-NP
O	1047	1050	and	and	CC	O
O	1051	1055	p300	p300	NN	B-NP
O	1056	1063	binding	binding	NN	I-NP
O	1063	1064	.	.	.	O

O	1065	1067	An	An	DT	B-NP
O	1068	1069	N	N	NN	I-NP
O	1069	1070	-	-	HYPH	B-NP
O	1070	1078	terminal	terminal	JJ	I-NP
O	1079	1086	segment	segment	NN	I-NP
O	1087	1097	containing	contain	VBG	B-VP
O	1098	1101	the	the	DT	B-NP
O	1102	1107	first	first	JJ	I-NP
O	1108	1111	127	127	CD	I-NP
O	1112	1113	T	T	NN	I-NP
O	1113	1114	-	-	HYPH	I-NP
O	1114	1121	antigen	antigen	NN	I-NP
O	1122	1127	amino	amino	JJ	I-NP
O	1128	1133	acids	acid	NNS	I-NP
O	1134	1135	(	(	(	O
O	1135	1137	T1	T1	NN	B-NP
O	1137	1138	-	-	HYPH	B-NP
O	1138	1141	127	127	CD	I-NP
O	1141	1142	)	)	)	O
O	1143	1146	was	be	VBD	B-VP
O	1147	1157	sufficient	sufficient	JJ	B-ADJP
O	1158	1160	to	to	TO	B-VP
O	1161	1170	sensitize	sensitize	VB	I-VP
B-Cell	1171	1176	cells	cell	NNS	B-NP
O	1176	1177	.	.	.	O

O	1178	1179	A	A	DT	B-NP
O	1180	1181	C	C	NN	I-NP
O	1181	1182	-	-	HYPH	B-NP
O	1182	1190	terminal	terminal	JJ	I-NP
O	1191	1198	segment	segment	NN	I-NP
O	1199	1209	consisting	consist	VBG	B-VP
O	1210	1212	of	of	IN	B-PP
O	1213	1214	T	T	NN	B-NP
O	1214	1215	-	-	HYPH	I-NP
O	1215	1222	antigen	antigen	NN	I-NP
O	1223	1228	amino	amino	NN	I-NP
O	1229	1234	acids	acid	NNS	I-NP
O	1235	1238	251	251	CD	B-NP
O	1239	1241	to	to	TO	B-PP
O	1242	1245	708	708	CD	B-NP
O	1246	1247	(	(	(	O
O	1247	1251	T251	T251	NN	B-NP
O	1251	1252	-	-	HYPH	B-NP
O	1252	1255	708	708	CD	I-NP
O	1255	1256	)	)	)	O
O	1257	1261	also	also	RB	B-ADVP
O	1262	1272	sensitized	sensitize	VBD	B-VP
B-Cell	1273	1278	cells	cell	NNS	B-NP
O	1279	1281	to	to	TO	B-PP
O	1282	1283	5	5	CD	B-NP
O	1283	1284	-	-	HYPH	I-NP
O	1284	1286	FU	FU	NN	I-NP
O	1286	1287	-	-	HYPH	B-NP
O	1287	1294	induced	induce	VBN	I-NP
O	1295	1304	apoptosis	apoptosis	NN	I-NP
O	1304	1305	.	.	.	O

O	1306	1310	This	This	DT	B-NP
O	1311	1324	sensitization	sensitization	NN	I-NP
O	1325	1328	did	do	VBD	B-VP
O	1329	1332	not	not	RB	I-VP
O	1333	1338	occur	occur	VB	I-VP
O	1339	1343	when	when	WRB	B-ADVP
O	1344	1348	T251	T251	NN	B-NP
O	1348	1349	-	-	HYPH	B-NP
O	1349	1352	708	708	CD	I-NP
O	1353	1356	was	be	VBD	B-VP
O	1357	1365	targeted	target	VBN	I-VP
O	1366	1368	to	to	TO	B-PP
O	1369	1372	the	the	DT	B-NP
B-Cellular_component	1373	1380	nucleus	nucleus	NN	I-NP
O	1381	1383	by	by	IN	B-PP
O	1384	1393	inclusion	inclusion	NN	B-NP
O	1394	1396	of	of	IN	B-PP
O	1397	1400	the	the	DT	B-NP
O	1401	1405	SV40	SV40	NN	I-NP
B-Cellular_component	1406	1413	nuclear	nuclear	JJ	I-NP
O	1414	1426	localization	localization	NN	I-NP
O	1427	1433	signal	signal	NN	I-NP
O	1433	1434	.	.	.	O

O	1435	1438	The	The	DT	B-NP
O	1439	1451	introduction	introduction	NN	I-NP
O	1452	1454	of	of	IN	B-PP
O	1455	1464	mutations	mutation	NNS	B-NP
O	1465	1469	into	into	IN	B-PP
O	1470	1473	the	the	DT	B-NP
O	1474	1475	T	T	NN	I-NP
O	1475	1476	-	-	HYPH	I-NP
O	1476	1483	antigen	antigen	NN	I-NP
O	1484	1485	J	J	NN	I-NP
O	1486	1492	domain	domain	NN	I-NP
O	1493	1501	resulted	result	VBD	B-VP
O	1502	1504	in	in	IN	B-PP
O	1505	1513	mutation	mutation	NN	B-NP
O	1513	1514	-	-	HYPH	B-NP
O	1514	1522	specific	specific	JJ	I-NP
O	1523	1526	and	and	CC	I-NP
O	1527	1535	variable	variable	JJ	I-NP
O	1536	1546	inhibition	inhibition	NN	I-NP
O	1547	1549	of	of	IN	B-PP
O	1550	1559	apoptosis	apoptosis	NN	B-NP
O	1559	1560	.	.	.	O

O	1561	1565	This	This	DT	B-NP
O	1566	1572	result	result	NN	I-NP
O	1573	1582	suggested	suggest	VBD	B-VP
O	1583	1587	that	that	IN	B-SBAR
O	1588	1594	either	either	CC	O
O	1595	1598	the	the	DT	B-NP
O	1599	1609	structural	structural	JJ	I-NP
O	1610	1612	or	or	CC	O
O	1613	1616	the	the	DT	B-NP
O	1617	1627	functional	functional	JJ	I-NP
O	1628	1637	integrity	integrity	NN	I-NP
O	1638	1640	of	of	IN	B-PP
O	1641	1644	the	the	DT	B-NP
O	1645	1646	J	J	NN	I-NP
O	1647	1653	domain	domain	NN	I-NP
O	1654	1656	is	be	VBZ	B-VP
O	1657	1665	required	require	VBN	I-VP
O	1666	1668	to	to	TO	I-VP
O	1669	1678	sensitize	sensitize	VB	I-VP
B-Cell	1679	1684	cells	cell	NNS	B-NP
O	1685	1687	to	to	TO	B-PP
O	1688	1697	apoptosis	apoptosis	NN	B-NP
O	1697	1698	.	.	.	O

O	1699	1708	Treatment	Treatment	NN	B-NP
O	1709	1711	of	of	IN	B-PP
B-Cell	1712	1715	REF	REF	NN	B-NP
O	1716	1718	or	or	CC	I-NP
B-Cell	1719	1722	REF	REF	NN	I-NP
O	1723	1733	expressing	express	VBG	B-VP
O	1734	1738	full	full	JJ	B-NP
O	1738	1739	-	-	HYPH	I-NP
O	1739	1745	length	length	NN	I-NP
O	1746	1747	T	T	NN	I-NP
O	1748	1755	antigen	antigen	NN	I-NP
O	1755	1756	,	,	,	O
O	1757	1759	an	an	DT	B-NP
O	1760	1761	N	N	NN	I-NP
O	1761	1762	-	-	HYPH	B-NP
O	1762	1770	terminal	terminal	JJ	I-NP
O	1771	1778	segment	segment	NN	I-NP
O	1778	1779	,	,	,	O
O	1780	1782	or	or	CC	O
O	1783	1787	T251	T251	NN	B-NP
O	1787	1788	-	-	HYPH	O
O	1788	1791	708	708	CD	B-NP
O	1792	1800	resulted	result	VBD	B-VP
O	1801	1803	in	in	IN	B-PP
O	1804	1813	increased	increase	VBN	B-NP
O	1814	1824	expression	expression	NN	I-NP
O	1825	1827	of	of	IN	B-PP
O	1828	1831	the	the	DT	B-NP
O	1832	1835	p53	p53	NN	I-NP
O	1835	1836	-	-	HYPH	B-NP
O	1836	1846	responsive	responsive	JJ	I-NP
O	1847	1851	MDM2	MDM2	NN	I-NP
O	1852	1856	gene	gene	NN	I-NP
O	1856	1857	;	;	:	O
O	1858	1867	apoptosis	apoptosis	NN	B-NP
O	1868	1876	occurred	occur	VBD	B-VP
O	1877	1884	through	through	IN	B-PP
O	1885	1886	a	a	DT	B-NP
O	1887	1890	p53	p53	NN	I-NP
O	1890	1891	-	-	HYPH	B-NP
O	1891	1900	dependent	dependent	JJ	I-NP
O	1901	1908	pathway	pathway	NN	I-NP
O	1908	1909	,	,	,	O
O	1910	1912	as	as	IN	B-SBAR
B-Cell	1913	1916	p53	p53	NN	B-NP
I-Cell	1916	1917	-	-	HYPH	I-NP
I-Cell	1917	1921	null	null	JJ	I-NP
I-Cell	1922	1927	cells	cell	NNS	I-NP
O	1928	1938	expressing	express	VBG	B-VP
O	1939	1944	these	these	DT	B-NP
O	1945	1946	T	T	NN	I-NP
O	1947	1955	antigens	antigen	NNS	I-NP
O	1956	1960	were	be	VBD	B-VP
O	1961	1970	resistant	resistant	JJ	B-ADJP
O	1971	1973	to	to	TO	B-PP
O	1974	1975	5	5	CD	B-NP
O	1975	1976	-	-	HYPH	I-NP
O	1976	1978	FU	FU	NN	I-NP
O	1978	1979	-	-	HYPH	B-NP
O	1979	1986	induced	induce	VBN	I-NP
O	1987	1996	apoptosis	apoptosis	NN	I-NP
O	1996	1997	.	.	.	O

O	1998	2006	Possible	Possible	JJ	B-NP
O	2007	2017	mechanisms	mechanism	NNS	I-NP
O	2018	2026	involved	involve	VBN	B-VP
O	2027	2029	in	in	IN	B-PP
O	2030	2041	sensitizing	sensitize	VBG	B-VP
B-Cell	2042	2047	cells	cell	NNS	B-NP
O	2048	2050	to	to	TO	B-PP
O	2051	2052	a	a	DT	B-NP
O	2053	2056	p53	p53	NN	I-NP
O	2056	2057	-	-	HYPH	B-NP
O	2057	2066	dependent	dependent	JJ	I-NP
O	2067	2076	apoptosis	apoptosis	NN	I-NP
O	2077	2084	pathway	pathway	NN	I-NP
O	2085	2087	in	in	IN	B-PP
O	2088	2093	spite	spite	NN	B-NP
O	2094	2096	of	of	IN	B-PP
O	2097	2100	the	the	DT	B-NP
O	2101	2108	ability	ability	NN	I-NP
O	2109	2111	of	of	IN	B-PP
O	2112	2113	T	T	NN	B-NP
O	2114	2121	antigen	antigen	NN	I-NP
O	2122	2124	to	to	TO	B-VP
O	2125	2129	bind	bind	VB	I-VP
O	2130	2133	and	and	CC	I-VP
O	2134	2144	inactivate	inactivate	VB	I-VP
O	2145	2148	the	the	DT	B-NP
O	2149	2164	transcriptional	transcriptional	JJ	I-NP
O	2165	2180	transactivating	transactivating	NN	I-NP
O	2181	2189	activity	activity	NN	I-NP
O	2190	2192	of	of	IN	B-PP
O	2193	2196	p53	p53	NN	B-NP
O	2197	2200	are	be	VBP	B-VP
O	2201	2210	discussed	discuss	VBN	I-VP
O	2210	2211	.	.	.	O

